Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 12/20 | 0.56 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498934 | 0.84 | NR1H4 (0.55) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL498233 | 0.84 | NR1H4 (0.62) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL497716 | 0.84 | NR1H4 (0.52) | NR1H4 | |
| SCHEMBL498161 | 0.81 | NR1H4 (0.69) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL497662 | 0.81 | NR1H4 (0.56) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL498243 | 0.81 | NR1H4 (0.59) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL498139 | 0.80 | NR1H4 (0.57) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL497577 | 0.78 | NR1H4 (0.60) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL498149 | 0.78 | NR1H4 (0.56) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL3164723 | 0.78 | NR1H4 (0.57) | NR1H4CCNKCCND3GSK3BCDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | NR1H4 1/4885CCNK 4580/4885CCND3 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.